Shares of Novavax Inc. (NASDAQ:NVAX) are trading higher Monday morning. The stock is extending its 30% monthly gains as investors respond positively to regulatory approvals across major jurisdictions for its updated protein-based COVID-19 vaccine ahead of the 2026–2027 autumn vaccination campaign, alongside broader sector strength bolstered by positive late-stage oncology clinical trial results across the biotech landscape.
Novavax shares are climbing with conviction. Why is NVAX stock surging?
Global Regulatory Clearances Validate Licensing Partnership Strategy
The momentum behind Novavax follows regulatory milestones secured late last week when the U.S. FDA granted approval for updated COVID-19 vaccines targeting dominant circulating variants.
Clearances for Novavax’s XFG-adapted Nuvaxovid vaccine alongside commercial partners Sanofi and Takeda ensure timely distribution heading into the fall immunization season.
